stock-detail (VSTM)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/17/2017 06:19 am

4/17/2017 06:19 am

4/17/2017 06:19 am

4/17/2017 06:19 am

4/9/2017 12:17 am

Verastem to Present at the 16th Annual Needham Healthcare Conference

4/3/2017 11:00 am

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 3:00 p.m.

Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting

4/2/2017 06:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase inhibitor, defactinib, by the Company’s scientific collaborator David G.

VERASTEM, INC. Financials

3/29/2017 05:00 pm

Verastem Reports Year-End 2016 Financial Results

3/23/2017 08:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate developments.

Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

3/16/2017 11:00 am

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.m.

Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference

3/15/2017 08:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21st at 2:10 p.m.

Verastem to Present at the 29th Annual ROTH Conference

3/7/2017 12:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29th Annual ROTH Conference on Monday, March 13th at 4:00 p.m.

Verastem to Present at 19th Annual BIO CEO & Investor Conference

2/7/2017 12:00 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th at 9:00 a.m.

Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer

1/26/2017 12:00 pm

[Business Wire] - Verastem, Inc., today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s defactinib**, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.

Verastem Announces Executive Leadership Appointments and Changes

1/19/2017 09:02 pm

[Business Wire] - Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.